Authors
Antonio Palumbo, Sara Bringhen, Heinz Ludwig, Meletios A Dimopoulos, Joan Bladé, Maria V Mateos, Laura Rosiñol, Mario Boccadoro, Michele Cavo, Henk Lokhorst, Sonja Zweegman, Evangelos Terpos, Faith Davies, Christoph Driessen, Peter Gimsing, Martin Gramatzki, Roman Hajek, Hans E Johnsen, Fernando Leal Da Costa, Orhan Sezer, Andrew Spencer, Meral Beksac, Gareth Morgan, Hermann Einsele, Jesus F San Miguel, Pieter Sonneveld
Publication date
2011/10/27
Source
Blood, The Journal of the American Society of Hematology
Volume
118
Issue
17
Pages
4519-4529
Publisher
American Society of Hematology
Description
Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the management of MM. The prevalence of MM is expected to rise over time because of an aging population. Most elderly patients with MM are ineligible for autologous transplantation, and the standard treatment has, until recently, been melphalan plus prednisone. The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has improved outcomes; however, elderly patients with MM are more susceptible to side effects and are often unable to tolerate full drug doses. For these patients, lower-dose-intensity regimens improve the safety profile and thus optimize treatment outcome. Further research into the best treatment strategies for vulnerable elderly patients is urgently needed. Appropriate …
Total citations
Scholar articles
A Palumbo, S Bringhen, H Ludwig, MA Dimopoulos… - Blood, The Journal of the American Society of …, 2011